Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Anxious Patients
NCT ID: NCT00355693
Last Updated: 2006-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
60 participants
INTERVENTIONAL
2006-10-31
2007-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The drug propofol, the agent most commonly used to induce general anaesthesia in the UK, is also frequently administered intravenously by anaesthetists in low doses to provide conscious sedation for patients undergoing unpleasant procedures i.e. patients become relaxed, anxiety-free, but maintain verbal contact throughout.
The technique of patient maintained sedation using the drug propofol (the patient can increase the amount of sedation (and propofol) they receive by pressing a demand button attached to a standard infusion device) has been used by anaesthetists and evaluated since 1997.
Several recent studies published and submitted for publication by this research group on patient maintained sedation using the drug propofol have shown this method of sedation to be safe and effective in dental patients (over 120 patients studied). It was also shown that this method, when compared to the established method of sedation in oral surgery (the dentist administering doses of midazolam intravenously), to produce both quicker recovery and less anxiety prior to the surgery.
The routine use of propofol traditionally is restricted to anaesthetists, as in high doses general anaesthesia is produced with possible loss of airway patency. Currently the safety feature is predominantly that as patients become more sedated they cannot press the patient demand button and hence cannot increase the amount of propofol they are receiving. Also the device ensures that the blood and brain concentrations have equilibrated to within 10% of each other before another successful demand for propofol can be made (usually takes approximately two minutes) and it only allows a maximum calculated brain concentration of 3 micrograms/milliliter of propofol. The device also will start to decrease the calculated brain concentration of propofol if the demand button has not been pressed for six minutes.
Despite the encouraging results above we also found in a recent pilot study involving 20 healthy volunteers who were instructed to try and make themselves unconscious that there were 2 cases of over sedation (of these one briefly lost verbal contact and the other required supplemental oxygen only). Over sedation, however, was not demonstrated with any of the oral surgery patients in the previous studies. This may have been due to a higher level of anxiety in dental patients affecting response to propofol.
We have therefore incorporated an additional safety feature into the existing and previously studied patient maintained sedation system which may further decrease or eliminate this small risk of over sedation. All the above safety features are retained and in addition the patient demand button will now also be used to monitor reaction time at one minutely intervals.
It is known that propofol slows the reaction time of a given individual and in another recent study of 40 patients undergoing general anaesthesia for planned surgery using propofol, the patients' reaction times were recorded both awake and during induction of anaesthesia by instructing the patients to press a button as quickly as possible in response to the handset vibrating. The calculated effect site (brain) concentration of propofol was increased incrementally and reaction time monitored at each stage until the patient could no longer press the button.
The data from this study (deteriorating patient reaction time with increased brain concentration of propofol) was analysed and this information used to provide an additional safety feature within the system to prevent over sedation i.e. a patient's reaction time deterioration by a certain percentage will prevent himself or herself being able to self-administer more propofol. Furthermore the system will actually start to decrease the brain concentration of propofol once the patients' reaction time becomes too slow. The patient demand button will be used to monitor reaction time at one minutely intervals as well as administer more propofol.
.
We hope that this will eliminate the small risk of over sedation and wish to conduct pilot studies to assess the safety and efficacy of this reaction time safeguarded, patient-maintained sedation system in three groups of twenty patients requiring sedation for planned procedures.
We have chosen two groups of dental patients, one group having oral surgery (technically more difficult dental work e.g. wisdom tooth removal) and one group having routine dentistry (e.g. patients having tooth fillings who are referred for sedation due to high anxiety levels). Another of our outcome measures will look at the effect of this technique on the patients' anxiety levels and we believe that this technique may be beneficial in reducing anxiety levels.
Patient maintained sedation has also been studied in 20 colonoscopy patients and found to be efficacious. However there were also 4 cases of slight over sedation, none of whom required any intervention e.g. airway or circulatory. We hope that by incorporating the reaction time safeguard that we can again eliminate this small risk.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pump for propofol delivery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 - 65
Exclusion Criteria
* Out with age group above
* Contraindication to propofol
* History of epilepsy
* History of substance abuse
* Major Psychiatric illness
* Pregnancy or breastfeeding
* Unable or unwilling to give informed consent
* Unable to use necessary apparatus
* Vulnerable groups
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Equity Partners (University Challenge Fund)
OTHER
University of Glasgow
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sonia Allam, MB ChB FRCA
Role: PRINCIPAL_INVESTIGATOR
University of Glasgow Dept of Anaesthesia
Conor P O'Brien, BDS FDS
Role: PRINCIPAL_INVESTIGATOR
Glasgow Dental Hospital & School
Avril Macpherson, MFDS MSND
Role: PRINCIPAL_INVESTIGATOR
NHS Lothian
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Glasgow Dental Hospital and School
Glasgow, Glasgow, United Kingdom
Duncan Street Dental Centre
Edinburgh, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Conor P O'Brien, BDS FDS
Role: primary
Sonia Allam, MB ChB FRCA
Role: backup
Avril Macpherson, BDS, MFDS RCSEd, MSND RCSEd
Role: primary
Francis Arnstein, MB ChB, FRCA
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9812/A
Identifier Type: -
Identifier Source: org_study_id